Videos

The interim chief of pediatric neurology at Stanford Medicine Children’s Health discussed progress in preventing seizures among patients with epilepsy, the potential for gene-targeted therapies, and the importance of localizing where seizures are coming from. [WATCH TIME: 5 minutes]

A medical expert discusses the findings of a randomized trial investigating the use of andexanet alfa versus usual care in patients with acute intracerebral hemorrhage (ICH) and recent direct oral anticoagulant (DOAC) use.

Neurology experts discuss the mechanism of action of BTKi’s for the treatment of multiple sclerosis.

Experts lead a discussion about potential safety concerns of BTKi’s when treating patients with multiple sclerosis.

The director of the headache section at Cleveland Clinic detailed some of the emerging nonpharmacological preventive methods for migraine, as well as where research is headed following the explosion of CGRP-targeting therapies. [WATCH TIME: 6 minutes]

Neurology News Network for the week ending November 25, 2023. [WATCH TIME: 4 minutes

The associate professor of clinical neurology at University of Miami Miller School of Medicine discussed the implications of findings from a recent post hoc analysis on midazolam and the need for inclusive research in assessing the efficacy of seizure rescue treatments. [WATCH TIME: 3 minutes]

The director of the Banner Sun Health Research Institute provided commentary on his presentation at CTAD 2023 examining the value of donanemab and its effect on specific Alzheimer-related assessments. [WATCH TIME: 10 minutes]

The associate professor of clinical neurology at the University of Miami Miller School of Medicine talked about findings from a recent post hoc analysis assessing the FDA-approved treatment of midazolam for seizure clusters. [WATCH TIME: 3 minutes]

Neurology experts discuss safety data for BTKIs.

Jiwon Oh, MD, PhD, FRCPC, provides an overview of phase II results of tolebrutinib for the treatment of multiple sclerosis.

Ahead of the 2024 MDA Conference, the vice president of public policy and advocacy at the Muscular Dystrophy Association talked about conference advocacy collaboration, access to treatments, and the state of healthcare. [WATCH TIME: 6 minutes]

Stuart J Connolly, MD, FRCPC, discusses updated strategies for managing intracerebral hemorrhage, emphasizing the significance of timely diagnosis to improve hemostatic efficacy.

The interim chief of pediatric neurology at Stanford Medicine Children’s Health provided insight on advances the screening for epilepsy surgery and the factors that pediatric neurologists should consider. [WATCH TIME: 5 minutes]

The director of the headache section at Cleveland Clinic’s Neurological Institute gave an administrative perspective on the changes to how patients with migraine are cared for, led by significant developments in recent years. [WATCH TIME: 4 minutes]

Neurology News Network for the week ending November 18, 2023. [WATCH TIME: 3 minutes]

The director of disability policy at the Muscular Dystrophy Association talked about the future possibility of having an aircraft that accommodates for patients with neuromuscular disorders who use mobility devices. [WATCH TIME: 3 minutes]

The physician neurologist and neuroimmunologist at Cedars Sinai Medical Center detailed the difficulties with discussing neuroimmune disorders with newly diagnosed patients, including those who may not speak English. [WATCH TIME: 3 minutes]

The multiple sclerosis (MS) experts advise health care providers on how to impact the early onset of disease progression and prevent neurodegeneration in patients with MS.

The neurologists discuss strategies to improve the cognitive health of patients with multiple sclerosis through physical and mental health multidisciplinary care.

The director of the headache section at Cleveland Clinic’s Neurological Institute provided commentary on the advances in the field of migraine and reasons to be excited about the 2023 AHS symposium in Scottsdale, Arizona. [WATCH TIME: 3 minutes]

The associate professor in the department of neurology and neurosurgery at McGill University discussed results from a study on the long-term use of continuous positive airway pressure treatment among patients with multiple sclerosis and sleep apnea presented at MSMilan 2023. [WATCH TIME: 5 minutes]

The physician neurologist and neuroimmunologist at Cedars Sinai Medical Center provided perspective on the patient-clinician relationships and the need to educate clinicians about the impacts of rare neuroimmune disorders in Spanish-speaking communities. [WATCH TIME: 3 minutes]

The neuromuscular neurologist at the Cleveland Clinic discussed findings from an analysis presented at AANEM 2023 that investigated the safety and efficacy of subcutaneous efgartigimod in patients with myasthenia gravis. [WATCH TIME: 5 minutes]

Episode 39 of the AUPN Leadership Minute features Donald S. Higgins Jr, MD, of Veterans Health Administration, Albany Medical College; and Alexandra Nelson, MD, PhD, of the University of California San Francisco. [WATCH TIME: 5 minutes]

The associate director of the Alzheimer’s Disease Research Unit at the Yale School of Medicine discussed the mechanism of action of ALX-001, a highly selective agent in development for neurodegenerative diseases. [WATCH TIME: 5 minutes]

The professor of neurology, psychiatry, and pharmacology at the NYU Grossman School of Medicine commented on the differences in mechanisms and clinical trial data between lecanemab and donanemab. [WATCH TIME: 5 minutes]

Amit Bar-Or, MD, FRCPC, summarizes fenebrutinib phase II results for the treatment of multiple sclerosis.

Patrick Vermersch, MD, PhD, summarizes phase II clinical trial of evobrutinib for the treatment of multiple sclerosis.

The founder of Strategic Advocacy Solutions LLC discussed the critical role of psychosocial support throughout various stages of neuromuscular diseases, emphasizing the impact of transitions on patients' emotional well-being. [WATCH TIME: 5 minutes]